A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial

• Published in: Thrombosis and haemostasis Vol. 116; no. 2; p. 241
• Main Authors: Whitlock, Richard P, Fordyce, Christopher B, Midei, Mark G, Ellis, Dave, Garcia, David, Weitz, Jeffrey I, Canafax, Daniel M, Albrecht, Detlef, Milner, Peter G
• Format: Journal Article
• Language: English
• Published: Germany 01.08.2016
• Subjects: Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Benzoates - administration & dosage; Benzoates - adverse effects; Coumarins - administration & dosage; Coumarins - adverse effects; Cytochrome P-450 CYP2C9 - genetics; Cytochrome P-450 CYP2C9 - metabolism; Double-Blind Method; Genotype; Heart Valve Prosthesis; Hemorrhage - prevention & control; Humans; Thromboembolism - prevention & control; Vitamin K - antagonists & inhibitors; Vitamin K Epoxide Reductases - antagonists & inhibitors; Warfarin - administration & dosage; Warfarin - adverse effects; CYP2C9; tecarfarin; Anticoagulation; warfarin

Tecarfarin is a novel vitamin K antagonist that is metabolised by carboxyl estererase, thereby eliminating the variability associated with cytochrome-mediated metabolism. EmbraceAC was designed to compare the quality of anticoagulation with tecarfarin and warfarin as determined by time in therapeuti...